cas 2233-18-3|| where to buy 3,5-Dimethyl-4-hydroxybenzaldehyde

Produktname:3,5-Dimethyl-4-hydroxybenzaldehyde

IUPAC Name:4-hydroxy-3,5-dimethylbenzaldehyde

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM184693-500g	in stock	Ǡœƴ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2233-18-3 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2233-18-3; Molekulare Formel:C9H10O2; Schmelzpunkt:-; SMILES-Code:C1=C(C=C(C)C(=C1C)O)C=O; Dichte:

: Katalognummer:CM184693; Molekulargewicht:150.18; Siedepunkt:263.9°C at 760 mmHg; Mdl-Nr.:MFCD00006946; Lagerung:Keep in Inert atmosphere, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Elafibranor; Nov 13, 2023, ELATIVE® Phase III trial confirms potential for investigational elafibranor as a first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis.
Elafibranor is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease. Concurrent α,δ activation targets inflammation, cholestasis and fibrosis in PBC.